Download PDF
Horm Metab Res 2016; 48(10): 653-657
DOI: 10.1055/s-0042-116155
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Association of Circulating Irisin with Insulin Resistance and Oxidative Stress in Obese Women

M. Belviranli
1   Department of Physiology Faculty of Medicine, Selçuk University, Konya, Turkey
,
N. Okudan
1   Department of Physiology Faculty of Medicine, Selçuk University, Konya, Turkey
,
F. Çelik
1   Department of Physiology Faculty of Medicine, Selçuk University, Konya, Turkey
› Author Affiliations
Further Information

Publication History

received 24 March 2016

accepted 22 August 2016

Publication Date:
15 September 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Irisin is a myokine/adipokine with potential role in obesity and diabetes. The purpose of the present study was to assess irisin levels and its association with insulin resistance and oxidative stress markers in premenopausal normal-weight and obese women. Ten obese (mean body mass index, 32.65±3.04 kg m−2) and 10 normal-weight (23.00±2.23 kg m−2) premenopausal women were involved in the present study. Anthropometric, and body composition parameters, blood chemistry, oxidative stress markers, and irisin concentrations of different groups were measured. Correlation analyses were performed between irisin and other measured parameters. Plasma irisin levels were lower in the obese group than the normal-weight group (p<0.05). Glucose, homeostasis model assessment index (HOMA-IR), and MDA levels in the obese group were higher than that in the normal-weight group (p<0.05). Plasma irisin was negatively correlated with insulin (r=−0.648, p<0.05), HOMA-IR (r=−0.664, p<0.05) and MDA (r=−0.690, p<0.05). These data suggest that irisin levels are decreased with obesity, and irisin may have an antidiabetic and antioxidant effects.

Key words

irisin - obesity - insulin resistance - oxidative stress
 

  • References

  • 1 WHO. 2014 Diabetes. (No. 312) [Factsheet]
    PubMedGoogle Scholar
  • 2 Poher AL, Altirriba J, Veyrat-Durebex C, Rohner-Jeanrenaud F. Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance. Front Physiol 2015; 30: 1-9
    PubMedGoogle Scholar
  • 3 Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G, Gitto E, Arrigo T. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 2014; 16: 378-400
    CrossrefPubMedGoogle Scholar
  • 4 Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
    CrossrefPubMedGoogle Scholar
  • 5 Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides 2014; 56: 94-110
    CrossrefPubMedGoogle Scholar
  • 6 Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis 2015; 14: 1-6
    CrossrefPubMedGoogle Scholar
  • 7 Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, García-Giménez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes 2012; 4: 196
    CrossrefPubMedGoogle Scholar
  • 8 Castillo-Quan JI. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech 2012; 5: 293-295
    CrossrefPubMedGoogle Scholar
  • 9 Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738
    CrossrefPubMedGoogle Scholar
  • 10 Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides 2013; 39: 125-130
    CrossrefPubMedGoogle Scholar
  • 11 Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 2013; 27: 365-369
    CrossrefPubMedGoogle Scholar
  • 12 Pardo M, Crujeiras AB, Amil M, Aguera Z, Jiménez-Murcia S, Baños R, Botella C, de la Torre R, Estivill X, Fagundo AB, Fernández-Real JM, Fernández-García JC, Fruhbeck G, Gómez-Ambrosi J, Rodríguez R, Tinahones FJ, Fernández-Aranda F, Casanueva FF. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014; 2014: 1-10
    PubMedGoogle Scholar
  • 13 Park KH, Zaichenko L, Peter P, Davis CR, Crowell JA, Mantzoros CS. Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism 2014; 63: 233-241
    CrossrefPubMedGoogle Scholar
  • 14 Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, Martínez JA, Casanueva FF. Longitudinal variation of circulating irisin after an energy restriction induced weight loss and following weight regain in obese men and women. Am J Hum Biol 2014; 26: 198-207
    CrossrefPubMedGoogle Scholar
  • 15 Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: 769-778
    CrossrefPubMedGoogle Scholar
  • 16 Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
    CrossrefPubMedGoogle Scholar
  • 17 Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor VM, Rocha M, Hernández-Mijares A, Romagnoli M. Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine 2014; 46: 674-677
    CrossrefPubMedGoogle Scholar
  • 18 Tremblay MS, Colley RC, Saunders TJ, Healy GN, Owen N. Physiological and health implications of a sedentary lifestyle. Appl Physiol Nutr Metab 2010; 35: 725-740
    CrossrefPubMedGoogle Scholar
  • 19 Pietrobelli A, Rubiano F, St-Onge MP, Heymsfield SB. New bioimpedance analysis system: improved phenotyping with whole-body analysis. Eur J Clin Nutr 2004; 58: 1479-1484
    CrossrefPubMedGoogle Scholar
  • 20 Sluyter JD, Schaaf D, Scragg RK, Plank LD. Prediction of fatness by standing 8-electrode bioimpedance: a multiethnic adolescent population. Obesity (Silver Spring) 2010; 18: 183-189
    CrossrefPubMedGoogle Scholar
  • 21 Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907
    CrossrefPubMedGoogle Scholar
  • 22 Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA, Perticone F. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 2014; 51: 705-713
    CrossrefPubMedGoogle Scholar
  • 23 Yuksel MA, Oncul M, Tuten A, Imamoglu M, Acikgoz AS, Kucur M, Madazli R. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract 2014; 104: 171-175
    CrossrefPubMedGoogle Scholar
  • 24 Amirkhizi F, Siassi F, Minaie S, Djalali M, Rahimi A, Chamari M. Is obesity associated with increased plasma lipid peroxidation and oxidative stress in women. ARYA Atheroscler J 2007; 2: 189-192
    PubMedGoogle Scholar
  • 25 Zhu D, Wang H, Zhang J, Zhang X, Xin C, Zhang F, Lee Y, Zhang L, Lian K, Yan W, Ma X, Liu Y, Tao L. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol 2015; 87: 138-147
    CrossrefPubMedGoogle Scholar
  • 26 Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761
    CrossrefPubMedGoogle Scholar
  • 27 Ozata M, Mergen M, Oktenli C, Aydin A, Sanisoglu SY, Bolu E, Yilmaz MI, Sayal A, Isimer A, Ozdemir IC. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem 2002; 35: 627-631
    CrossrefPubMedGoogle Scholar